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Sepsis is a major health problem worldwide. As the number of sepsis cases increases, so does the number of
sepsis survivors who suffer from “post-sepsis syndrome” after hospital discharge. This syndrome involves
deficits in multiple systems, including the immune, cognitive, psychiatric, cardiovascular, and renal systems.
Combined, these detrimental consequences lead to rehospitalizations, poorer quality of life, and increased
mortality. Understanding the pathophysiology of these issues is crucial to develop new therapeutic opportu-
nities to improve survival rate and quality of life of sepsis survivors. Such novel strategies include modulating
the immune system and addressing mitochondrial dysfunction. A sepsis follow-up clinic may be useful to
identify long-term health issues associated with post-sepsis syndrome and evaluate existing and novel strat-
egies to improve the lives of sepsis survivors.
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Sepsis is a dysregulated host response to infection that can eventu-
ally lead to multi-organ failure (MOF) and is one of the most common
causes of death among hospitalized patients [1,2]. Sepsis caused one in
five of all global deaths in 2017 (»11million deaths/489million cases)
[2] and is the most common complication amongst COVID-19 patients
[3]. Despite much research, little is known about the precise pathogen-
esis of sepsis, and therapy remains limited to source control (e.g. drain-
age, antibiotics) and supportive care, [1,4] which can improve mortality
and prevent MOF in some, but not all patients, particularly if not
administered in the critical early hours [4,5]. There is scarce data that
describes the long-term consequences of sepsis and how to optimize
health post-sepsis. Mortality rates after surviving the initial sepsis epi-
sode remain high: depending on sepsis severity, the one-year post-dis-
charge mortality rate varies between 7-43%, [6] and five-year mortality
rate after severe sepsis is 82% [7]. Half of the deaths after sepsis are
caused by recurrent infection and cardiovascular events [8]. Long-term
mortality is often due to the so-called “post-sepsis syndrome”: a phe-
nomenon defined as consistent physical, medical, cognitive, andpsychological issues after sepsis [9]. Post-sepsis syndrome increases
readmission risk for infections and the incidence of cognitive
impairment, mental health problems, renal failure, and cardiovascular
events, compared to non-sepsis hospitalized patients [1013]. Here,
we provide a critical summary of the current understanding of the
post-sepsis syndrome and discuss opportunities to optimize health and
life span after sepsis.
2. Rehospitalization risk
Almost a third of all sepsis survivors are readmitted to the hospital
within 90 days, [12] while nearly half of the patients over 50 years of
age are readmitted within 90 days [11]. Up to a third of these read-
missions are due to recurrent sepsis, [11,12] while other common
causes are heart failure, pneumonia and acute renal failure (together
»15%) [11]. Sepsis survivors have a two-fold higher incidence of sep-
sis and nearly three-fold higher incidence of acute renal failure as
compared to age and comorbidity-matched subjects surviving hospi-
talizations for other acute medical diagnoses [11]. Recurrent sepsis
remains a problem years after discharge as over an eight-year period,
more sepsis survivors develop recurrent sepsis compared to ran-
domly sampled patients from a health registry (35% versus 4%), [14]
while recurrent sepsis caused nearly one third of deaths in sepsis sur-
vivors during this period [14]. Thus, rehospitalization and mortality
due to sepsis recurrence and non-septic causes constitute a lethal
problem for sepsis survivors.
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patients at risk for sepsis are largely the same risk factors for recur-
rence, such as increased age, cardiovascular and kidney disease,
frailty, and cognitive impairment [15]. Moreover, sepsis induces a
state of persistent low-grade inflammation, [16] prolonged immune
dysregulation, [16] and mitochondrial dysfunction, [17,18] which
results in increased infection risk and cellular damage, thereby mak-
ing survivors more vulnerable to recurrent sepsis episodes. Possible
strategies to prevent recurrent infection include active surveillance
of re-infections, prophylactic antibiotics, vaccination, and when pos-
sible, minimizing the use of invasive devices (e.g. indwelling urinary
catheters, pacemakers, or intravascular lines), and avoiding drugs
that suppress the immune system, such as cancer chemotherapy and
direct immune suppressive drugs [19,20]. However, these strategies
may not be feasible in all situations and are associated with side-
effects, including the risk of antibiotic resistance, while avoiding
invasive devices or immunosuppressive drugs may not be possible
for those in need of these therapies. Thus, to enhance health and life
span after sepsis, it is necessary to identify feasible strategies to lower
the risk factors that predispose patients to recurrent sepsis episodes.
3. Prolonged immunosuppression
While sepsis was historically thought of as a predominantly
hyper-inflammatory syndrome, recent focus has been expanded to
the occurrence of an immunosuppressive phase, occurring concur-
rently with the hyperinflammatory phase, [21] which is marked by
lymphocyte apoptosis [22] and cellular reprogramming (endotoxin
tolerance) of innate immune cells [23]. Immunosuppression is evi-
dent early in sepsis, and persists after patient discharge [24]. Pro-
longed immunosuppression is a key component of the post-sepsis
syndrome as it seems to underlie the high rate of lethal infections
and sepsis recurrence [11,12]. One in five ICU sepsis survivors had
positive blood cultures up to 150 days after sepsis, among which
there were more opportunistic bacterial and Candida infections than
during admission, suggesting a prolonged inability to clear infections
[25]. This has important clinical consequences since, 73% of deaths in
a cohort of 78 ICU sepsis survivors one year post-discharge were due
to infectious complications, predominantly from pneumonia and uri-
nary tract infections, compared to 11% in 50 non-septic ICU survivors
[26]. A high frequency of lethal secondary bacterial and fungal
infections in hospitalized COVID-19 patients, [27] many of whom
develop sepsis, [3] suggests a similar immunosuppressive phenotype,
although it is as-yet unknown how long this immunosuppression
persists. Sepsis survivors have reduced pro-inflammatory interleu-
kin-6 (IL-6) and tumor necrosis factor alpha (TNFa) secretion after
stimulation of whole-blood with zymosan (a yeast surface protein),
as well as a substantial decrease in anti-inflammatory IL-10 secretion
in response to lipopolysaccharide (LPS) at 9-52 months after dis-
charge, when compared to healthy controls, [24] indicating a sus-
tained inability of immune cells to mount an effective immune
response.
4. Mechanisms underlying sepsis-induced immune dysregulation
4.1. Epigenetic changes
The prolonged immunosuppressive phase may, amongst others,
be explained by epigenetic mechanisms reprogramming innate and
adaptive immune cells. Altered DNA methylation and histone modifi-
cations are observed in human patients and murine models post-sep-
sis and result in repressed expression of immune-related genes
encoding TNFa, IL-1ß, IL-12, and chemokine ligand 2 (CXCL-2/MIP2-
a) in macrophages and dendritic cells, [2830] and interferon
gamma (IFNg) in CD4+ T-cells [31]. Murine bone marrow progenitors
have repressive epigenetic modifications affecting inflammatorygene promoters four weeks after sepsis, producing macrophages
resembling the impaired macrophages found in sepsis survivors [32].
This provides a potential cause as to why new innate immune cells
formed after the initial septic episode appear to remain “reprog-
rammed”.4.2. Long-term effects on immune cell numbers
Sepsis carries long-term effects on adaptive immunity. Acute
sepsis leads to decreased numbers of CD4+ and CD8+ T-cells due to
apoptosis, [33,34] followed by reversal to levels found in healthy
individuals at six months after discharge [24]. However, despite
numerical recovery of T-cells, CD4+ T-cells have impaired immune
responses to ex-vivo stimulation by Aspergillus antigen [35] and
memory CD8+ T-cells have decreased antigen sensitivity (as demon-
strated in post-sepsis mice), [36] while stimulation of whole-blood
from sepsis survivors with T-cell activator (a-CD3/28) leads to a
lower IFNg secretion as compared to healthy controls [24]. These
long-term functional deficits may be due to the presence of immature
neutrophils and granulocytes, called myeloid derived suppressor cells
(MDSCs), which have T-cell suppressing capabilities [37]. Number of
circulating MDSCs are elevated during sepsis and remain elevated up
to at least four weeks after discharge [37]. Furthermore, sepsis is
associated with increased number of regulatory T-cells, which per-
sists for at least five to ten months afterwards [38]. As regulatory T-
cells play an important role in dampening immune responses, their
increased numbers may well contribute to persistent immunosup-
pression [38].4.3. Immunological endotypes associated with poor long-term outcome
Recent studies have described the ability to stratify patients with
sepsis into two to four different phenotypes, using (retrospective)
clinical data [39] or whole-blood transcriptome data [40,41]. Stratifi-
cation of septic ICU patients into four endotypes based on whole-
blood transcriptome analysis identified an endotype with decreased
expression of key regulators and components of the innate (e.g.
decreased toll-like receptor expression, nuclear factor-kB and inter-
feron signaling and antigen presentation) and adaptive (e.g. reduced
IL-4 and T-cell signaling and overall reduction in T-/B-cell receptor
signaling) immune system that was associated with the highest mor-
tality rates, both at 28-days and one-year after discharge [40]. These
genes encoding proteins involved in innate and adaptive immunity
that are reduced in expression during sepsis [40] remain expressed
at lower levels in sepsis survivors when compared to healthy controls
[24,31]. Conversely, the endotype with the lowest mortality had
increased expression of key genes involved in adaptive immune reg-
ulation (e.g. genes involved in T-helper cell signaling, IL-4 signaling,
and B-cell development), supporting the concept that functional res-
toration of T-cells might reverse post-sepsis immunosuppression.4.4. Therapeutic opportunities
Epigenetic reprogramming of immune cells and changes in the
number and function of lymphocytes appear to induce sustained
immunosuppression and thereby increase susceptibility to infection
in sepsis survivors (Fig. 1). Epigenetic marks can be modified in vitro
to reprogram immune cells (e.g. via histone deacetylase inhibitors),
[42] although such therapies have not been clinically tested. Thera-
pies such as IL-7 or checkpoint inhibitors are currently in human tri-
als and show potential to reverse long-term T-cell dysfunction in
sepsis patients [33,43]. However, until such strategies are available,
active surveillance of sepsis survivors and infectious disease control
measures are the best bets to prevent recurrent episodes of sepsis.
Fig. 1. Immune dysfunction in sepsis survivors. Early in sepsis, both inflammation and immunosuppression occur concurrently. If inflammation is uncontrolled, this leads to organ
failure and death. Those that avoid early death will either return to immune homeostasis, or progress to prolonged immunosuppression that continues after discharge. Prolonged
immunosuppression predisposes survivors to infections, rehospitalizations, and ultimately late death. This phenomenon is marked by impaired cytokine secretion, dysfunctional
T-cells, and cellular reprogramming. It is still unknownwhy prolonged immunosuppression occurs; however, epigenetic processes may be involved to “lock in” certain immunophe-
notypes. Expansion of regulatory T-cells and myeloid derived suppressor cell (MDSC) populations also occur early in sepsis and persist after sepsis, suggesting their role in maintain-
ing this immunosuppressive phenotype. TNFa: tumor necrosis factor alpha, IL-6: interleukin-6, DAMPs: damage-associated molecular patterns, Treg: regulatory T-cell, MDSC:
myeloid derived suppressor cell.
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Long-term cognitive issues, with deficits in processing speed,
attention span, perception, and memory, are a debilitating conse-
quence of sepsis [7,44,45]. These deficits affect up to one in five sepsis
survivors [44] and can last for up to three years [46]. Persistent cogni-
tive deficits lead to a poorer quality of life [47] and an increased risk
of rehospitalization [48]. Sepsis survivors have a reduced hippocam-
pal volume [49] and evidence of blood brain barrier (BBB) break-
down, as detected using magnetic resonance imaging (MRI) [50].
Murine sepsis survivors have increased rates of apoptosis in hippo-
campal neurons, [51] increased BBB permeability, [52] and ATP
depletion [53]. The occurrence of delirium in sepsis is strongly associ-
ated with long-term cognitive issues [54]. Delirium occurs in almost
one in four sepsis patients [55] and approximately half of the ICU
sepsis patients [56] and is associated with a high mortality rate [55].
Risk factors include acute renal failure, hyperglycemia, and electro-
lyte imbalances during hospitalization [57].
The association between delirium and long-term cognitive deficits
might be due to permanent damage induced by cerebral inflamma-
tion and ischemia, which is part of the pathophysiology of delirium
in sepsis [45,58]. Cerebral inflammation secondary to systemic
inflammatory mediators (e.g. TNFa, IL-1b, IL-6) leads to release of
damage associated molecular patterns (DAMPs, e.g. high-mobility
group protein 1; HMGB-1) that increase BBB permeability, thereby
allowing entry of cytokines into the brain, and microglial cell activa-
tion [59,60]. Neutralizing HMGB-1 one week after sepsis preserves
spatial memory of mice, illustrated by better performance in a timed
maze test [61]. Additionally, cerebral ischemia due to hypotension,
hypoxia, and microvascular occlusion due to disseminated intravas-
cular coagulation can cause damage, with one in three sepsis patients
having (multiple) cerebral infarctions [62]. Glucose and oxygen dep-
rivation from these infarctions leads to mitochondrial dysfunction
and oxidative damage, [63] which results in neuronal apoptosis and
cognitive dysfunction in septic rats [53]. Inducing mitochondrial bio-
genesis to increase mitochondrial mass improves cerebral ATP levelsand cognition [53]. Consequently, therapies aimed at preserving cere-
bral mitochondrial homeostasis may prevent cognitive impairment
post-sepsis.
6. Neuropsychiatric consequences
Severe sepsis (and other severe, acute illnesses that warrant ICU
admission) can have a long-lasting effect on mental health [64,65].
Post-traumatic stress disorder (PTSD) is a common diagnosis in criti-
cal illness survivors. Nearly half of critical illness survivors suffer
from PTSD at six months after discharge, which is associated with
increased rates of substance abuse and sleep disturbances [65,66].
Depression and anxiety are seen in up to a third of survivors of critical
illness three months after discharge [67,68]. The mental health issues
of post-sepsis syndrome and “post-intensive-care unit syndrome”
seem to overlap, and it is unclear whether sepsis causes any unique,
lasting neuropsychiatric changes. Thus, interventions to improve
mental health in ICU patients are likely applicable to sepsis patients.
The exact pathology of PTSD after sepsis is unknown, although it
might be triggered by severe illness and associated ICU admission
[69]. Interventions to improve ICU care, such as daily sedative inter-
ruption to prevent continuous altered mental status during the ICU
stay [70] or being seen by an intra-ICU clinical psychologist [71]
reduces symptoms of PTSD in survivors of critical illness. Specifically
for sepsis, cerebral damage may predispose to PTSD, anxiety, and
depression, especially if the limbic system is affected [72]. Human
sepsis survivors have signs of hypothalamic atrophy on MRIs, [49]
while murine sepsis models reveal irreversible structural brain dam-
age in the hippocampus and amygdala [50,72,73]. One intervention
to manage PTSD after sepsis is keeping an ICU diary, written by
healthcare workers or family during ICU stay, which is associated
with a decreased incidence of PTSD (5% compared to 13% without an
ICU diary) [74]. A one-year intervention involving primary care
physicians and nurses trained in post-sepsis care also prevented an
increase in PTSD symptoms in sepsis survivors two years after dis-
charge [75]. The REPAIR clinical trial, which is currently in progress,
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of reducing PTSD symptoms after sepsis [64].
7. Cardiovascular and kidney disease
Sepsis survivors have an increased risk of fatal cardiovascular and
kidney diseases, including stroke, myocardial infarction, heart failure,
ventricular arrhythmia, and chronic kidney disease (CKD) [7678]. The
development of CKD is closely related to cardiovascular disease and
may either share the same pathophysiology or be secondary to the
occurrence of cardiovascular disease [77,78]. Acute kidney injury (AKI),
which occurs in 30-50% of patients at the ICU and is frequently due to
sepsis, [77,79] is associated with increased mortality during sepsis (67%
compared to 43% in sepsis without AKI and 43% in AKI without sepsis)
[80]. Similarly, patients with pre-existing CKD have a two-fold
increased 90-day mortality risk when compared to septic patients
without CKD [81]. Sepsis-AKI is associated with a higher risk of CKD
development, [78] which also increases the risk of sepsis recurrence
[81,82]. Thus, sepsis, cardiovascular, and kidney disease are closely
intertwined, making it difficult to establish if patients were more prone
to sepsis due to pre-existing (undiagnosed) renal/cardiac problems, or
whether sepsis caused development of new problems.
The close relationship between these diseases may be explained
by mitochondrial dysfunction. Sepsis causes alterations in mitochon-
drial architecture, damage to mitochondrial DNA, and a decrease in
mitochondrial mass [18,83]. Whether mitochondrial damage is
repaired after sepsis is unknown, although mice show persisting
mitochondrial DNA damage four days post-sepsis [18]. Besides mito-
chondrial damage, sepsis is also associated with mitochondrial dys-
function (i.e. lowered mitochondrial membrane potential, ATP
production, increased mitochondrial reactive oxygen species; ROS)
[4,17,84]. Mitochondrial dysfunction seems to play a key role in the
induction of sepsis-AKI, [85,86] and mitochondria-targeted antioxi-
dants prevents AKI and lowers mortality in murine sepsis [87]. In
addition, mitochondrial-targeted antioxidants decrease oxidative
stress, improve mitochondrial- and organ function, and increase
three day survival after sepsis in rat [87,88]. Other potential interven-
tions include inhibition of mitochondrial ROS production to prevent
mitochondrial- and cell damage, and inducing mitochondrial biogen-
esis to restore mitochondrial mass and oxidative metabolism [83,89].
Further implicating a key role of mitochondria during sepsis, is the
impaired cardiac mitochondrial function which reduces calcium
uptake leading to sarcomere destruction, contractile dysfunction and
heart failure, [90,91] while renal mitochondrial dysfunction is associ-
ated with development of CKD [92,93]. Thus, mitochondrial dysfunc-
tion seems to play a key role in the pathophysiology of both sepsis,
cardiovascular, and kidney diseases. Consequently, preserving mito-
chondrial function in sepsis may not only prevent the induction of
organ injury during sepsis, but also improve long-term outcomes
after sepsis.
In addition to molecular changes induced by sepsis, classic cardio-
vascular risk factors also increase cardiovascular and kidney disease
risk among sepsis survivors. As such, obesity is associated with an
increased one year mortality risk after sepsis as compared to non-
obese survivors [94]. Therefore, sepsis survivors should be counseled
for cardiovascular risks with attention to weight, blood pressure
management, healthy lifestyle choices, and perhaps most impor-
tantly, high-density lipoprotein (HDL) management [95]. Not only do
low levels of HDL and high amounts of low-density lipoprotein (LDL)
increase the risk of cardiovascular events and CKD, [96,97] but low
levels of HDL in (recurrent) sepsis are associated with an increased
risk of organ failure, ICU admission, and mortality [96]. While the
association with poor prognosis could be attributed to underlying
pre-existing cardiovascular disease, sepsis itself also distorts lipid
metabolism [98]. Decreased HDL levels can be used as prognostic
marker for early organ failure and mortality, [98,99] which has beenattributed to the ability of HDL to bind and neutralize LPS, [100] act
as an immunomodulator, and preserve endothelial function
[100,101]. Thus, low HDL levels increase the risk of organ failure and
mortality in (recurrent) sepsis and is associated with cardiovascular
and kidney disease among sepsis survivors.
Statins and modulation of HDL levels might reduce the risk of car-
diovascular events among sepsis survivors. However, cholesterol
management remains controversial since low levels of LDL are also
associated with an increased sepsis risk [102]. One reason cholesterol
management may work is that persistent, low-grade systemic
inflammation in sepsis, that can occur simultaneously with immuno-
suppression, [16,103] may destabilize atherosclerotic plaques which
could lead to plaque rupture and cause a stroke or myocardial infarc-
tion [104,105]. Pre-treatment of mice with statins before sepsis
[106108], or after sepsis [109], improves survival, possibly due to
plaque stabilization combined with decreased ROS production and
immunomodulatory effects [106,110]. Additionally, treatment of
mice with statins after sepsis lowers neuroinflammation, endothelial
dysfunction, and cognitive decline [111] and statins use in patients
with atherosclerosis is associated with a reduced sepsis risk [110].
Experimental modulation of HDL levels by administration of ApoA1-
mimetic peptides or reconstituted HDL in animal models of sepsis
decreases inflammation, organ damage, and mortality [101,112].
Since a gain-of-function mutation in cholesteryl ester transfer protein
(CETP) is associated with lower HDL levels and higher mortality in
sepsis, [113] increasing HDL levels using CETP inhibitors seems to be
another promising strategy [113]. Whether restoring HDL levels will
also reduce cardiovascular and kidney disease among sepsis survivors
is as-yet unknown. Overall, sepsis survivors suffer from a high risk of
cardiovascular and kidney disease, although it is unclear if the under-
lying pathophysiology is the same as non-sepsis-associated develop-
ment of cardiovascular and kidney disease. If not, classic
cardiovascular risk management strategies may be insufficient to
prevent cardiovascular problems after sepsis and the focus of new
therapies should move towards targeting underlying mechanisms,
including mitochondrial dysfunction.
8. Overall functioning and quality of life
Sepsis survivors continue to have a reduced health-related quality
of life (QoL) for at least five years after discharge, particularly in the
physical domain, when compared to age-matched controls [114].
Similarly, almost half of acute COVID-19 survivors reported
decreased QoL 60 days after first onset of symptoms compared to
before developing COVID-19, mainly due to fatigue and joint pain
[115]. Decreased physical function may be due to loss of muscle mass
during sepsis, though it is incompletely understood why muscle
regeneration is impaired after sepsis [116]. Mitochondrial dysfunc-
tion, as seen in in muscle stem cells in septic mice, may well underlie
impaired muscle regeneration in sepsis survivors [18]. Consequently,
poor physical functioning leads to inability to work in more than half
of previously-employed sepsis survivors [116]. A poor QoL six
months after sepsis is predictive of a worsening QoL one year after
sepsis; [117] therefore, it is key to identify patients with early
decreases in QoL who may need closer follow-up and personalized
strategies to improve QoL.
Physiotherapy can improve physical QoL after sepsis. Initiation of
physical rehabilitation within three months after discharge not only
improved physical strength, but also reduced ten-year mortality in
sepsis survivors, as compared to sepsis survivors who did not receive
physiotherapy [118]. Furthermore, early mobility interventions
improve physical function at discharge, as compared to patients who
received only primary care during sepsis [119]. The benefits of phys-
iotherapy are likely mediated by improved mitochondrial function
and reduced inflammation, which then improves both physical and
cognitive health [120,121]. Based on the molecular mechanisms
E.C. van der Slikke et al. / EBioMedicine 61 (2020) 103044 5underlying the reduced physical function after sepsis in mice, [18]
mesenchymal stem cell therapy seems to be a promising adjuvant
future therapy to improve muscle strength and overcome impaired
muscle regeneration via restoration of mitochondrial function in
muscle cells.
9. Current and future therapeutic opportunities to optimize long-
term outcome after sepsis
Post-sepsis syndrome consists of immunological, cardiovascular,
and cognitive deficits that persist long after hospital discharge,
resulting in more frequent rehospitalizations due to recurrent sepsis,
decreased QoL, and increased comorbidity and mortality (Fig. 2). A
sepsis follow-up clinic seems to be a useful strategy to allow doctors
and scientists to provide post-sepsis care while collecting relevant
data from sepsis survivors, performing clinical trials to determine
optimal post-sepsis rehabilitation strategies, and expanding insights
into the mechanisms that underlie the long-term consequences of
this syndrome. We propose that endotype stratification during sepsis,
based on clinical and/or molecular data, can identify patients at
increased risk for the development of post-sepsis syndrome; [40] this
strategy will also expand fundamental knowledge about the patho-
physiology of post-sepsis syndrome with relevance to the develop-
ment of novel therapies. In addition, mitochondrial dysfunction isFig. 2. Current and future strategies to combat post-sepsis syndrome. Many sepsis survivor
immune dysfunction, cognitive deficits, mental health problems, and cardiovascular/kidney
drome will lead to rehospitalization and recurrent sepsis, placing the patient in a lethal feed
diovascular risk management, statins, and physiotherapy. Future therapies include reversin
HDL restoring therapies, mesenchymal stem cell therapy and risk stratification based on en
care worker, ICU: intensive care unit, DAMP: damage-associated molecular pattern, ROS: rea
smart.servier.com), licensed under a Creative Common Attribution 3.0 Generic License.linked to the development and progression of chronic diseases partic-
ularly after sepsis, including cardiovascular, neurodegenerative, and
kidney disease [18,63,85]. Consequently, preventing mitochondrial
damage during sepsis or restoring mitochondrial function could
counteract the long-term effects of sepsis on health and life span.
Table 1 summarizes the clinically relevant long-term consequences
after sepsis and novel treatments that might resolve or prevent these
sequelae.
10. Conclusion
Overall, the pathophysiology of sepsis and post-sepsis syndrome
remains poorly understood mainly due to its heterogeneous nature,
thereby making it hard to treat. Injury occurring during sepsis is
likely only partially repaired, leaving sepsis survivors with post-sep-
sis syndrome. Therefore, we should realize that sepsis is more than
an intermittent acute disease. Long-term effects of the post-sepsis
syndrome consist of persistent immune, cognitive, neuropsychiatric,
and cardiovascular dysfunctions, resulting in frequent rehospitaliza-
tion, increased mortality, and decreased quality of life compared to
survivors of other acute medical conditions. Understanding the path-
ophysiology of these aspects of post-sepsis syndrome has led to the
development of the mechanism-guided therapies listed in this
review; however, few clinical trials have been done to test theses suffer from at least one aspect from post-sepsis syndrome, which is characterized by
disease, causing decreased quality of life and mortality. Left untreated, post-sepsis syn-
back loop. Follow up strategies include infection control, improving mental health, car-
g immune dysfunction, prevention of mitochondrial damage, inhibiting DAMP release,
dotype. (BBB: blood brain barrier, PTSD: post-traumatic stress disorder, HCW: health
ctive oxygen species). Fig. 2 was created with images from Servier Medical Art (http://
Table 1
Post-sepsis syndrome sequelae, their proposed pathophysiology, and current or future strategies that target these pathophysiological mechanisms.
Post-Sepsis Syndrome Sequelae Proposed Pathophysiology Current Strategies Future Strategies
Persistent immune dysfunction,[24]






Increased regulatory T cells[38]
Promoting infection control practices
Prophylactic antibiotics
Vaccinations
Minimizing use of invasive devices




Risk stratification based on endotype
[3941]
Cognitive impairment Cerebral inflammation[60,61]
Cerebral ischemia,[62] leading to mito-
chondrial dysfunction[50]
Sending patients to long-term care
homes
Targeting DAMPs (e.g. HMGB-1) to pre-
vent cerebral damage[61]
Reversing mitochondrial dysfunction (e.
g.mitochondrial biogenesis)[53]
Post-traumatic stress disorder Traumatic experiences in the ICU[69]
Cerebral damage, especially in the limbic
system[72]
Avoiding continuous sedative use in ICU
[70]
Being seen by an ICU psychologist[71]
Care by healthcare workers trained in
post-sepsis care[75]
Maintaining an “ICU diary”[74]
Cognitive behavioural therapy[64]
Preventing or reversing cerebral damage
[53,61]
Cardiovascular disease Mitochondrial dysfunction
Cardiovascular risk factors (e.g. high BMI,
blood pressure, cholesterol levels)
[4,17,18,83]






(inhibition of mitochondrial ROS pro-
duction, increasing mitochondrial bio-
genesis)[83,89]
HDL increasing agents[100,101,113]
Decreased quality of life Impaired muscle regeneration due to
mitochondrial dysfunction[18]
Physiotherapy and physical rehabilita-
tion[118,119]
Mesenchymal stem cell therapy[18]
6 E.C. van der Slikke et al. / EBioMedicine 61 (2020) 103044interventions, perhaps due to the difficulty of finding, enrolling, and
following up with sepsis survivors, problems which a post-sepsis
clinic may alleviate. Immune endotypes and mitochondrial dysfunc-
tion seem to be of substantial importance in defining patient out-
comes and improving those features using future therapies might
ultimately improve the health and life span of sepsis survivors.
Outstanding questions
1. What is the efficacy of using post-sepsis clinics to alleviate symp-
toms of post-sepsis syndrome?
2. Which specialties should be involved in the multidisciplinary
post-sepsis team?
3. What role does mitochondrial dysfunction play in multiple
aspects of post-sepsis syndrome?
4. What is the best way to stratify sepsis survivors to individualize
follow-up care? Could endotype stratification be a possibility?
5. With emerging evidence of COVID-19 survivors with persistent
symptoms similar to post-sepsis syndrome, are these two phe-
nomena related, and if so, can therapeutics outlined in this
review help COVID-19 survivors?
Search strategy and selection criteria
Articles for this review were identified using PubMed, Google
Scholar, and references from relevant articles using the search terms:
‘Sepsis’ OR ‘Post-sepsis syndrome’, AND ‘Rehospitalization’ OR ‘Long-
term outcome’ OR ‘Immune system’ OR ‘Quality of life’ OR ‘Cognitive
dysfunction’ OR ‘Cardiovascular system’ OR ‘Chronic kidney disease
OR ‘Psychiatric disorder’. Only the most impactful papers were con-
sidered.
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